Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EBT (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed EBT for 7 consecutive years, with -$98.0 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 21.25% to -$98.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$349.8 million, a 33.56% decrease, with the full-year FY2025 number at -$349.8 million, down 33.56% from a year prior.
  • EBT was -$98.0 million for Q4 2025 at Kymera Therapeutics, down from -$92.6 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$13.2 million in Q1 2021 to a low of -$98.0 million in Q4 2025.
  • A 5-year average of -$54.3 million and a median of -$48.2 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: soared 49.95% in 2023, then plummeted 317.34% in 2024.
  • Kymera Therapeutics' EBT stood at -$24.8 million in 2021, then crashed by 56.27% to -$38.7 million in 2022, then skyrocketed by 49.95% to -$19.4 million in 2023, then tumbled by 317.34% to -$80.8 million in 2024, then fell by 21.25% to -$98.0 million in 2025.
  • Per Business Quant, the three most recent readings for KYMR's EBT are -$98.0 million (Q4 2025), -$92.6 million (Q3 2025), and -$84.7 million (Q2 2025).